Evommune, Inc. (EVMN)
NYSE: EVMN · Real-Time Price · USD
7.04
-0.20 (-2.76%)
At close: Nov 20, 2026, 4:00 PM EST
7.03
-0.01 (-0.14%)
After-hours: Nov 20, 2026, 7:30 PM EST
Evommune Market Cap
Evommune has a market cap or net worth of $291.1 million as of November 20, 2026. It is the 17,545th most valuable company in the world and the 3,119th biggest in the United States. Its market cap has decreased by 49.83% in one year.
Market Cap
291.10M
Enterprise Value
130.66M
1-Year Change
-49.83%
Global Rank
Country Rank
#3,119 United States
Category
ChartMarket Cap Chart
Since the IPO on November 6, 2025, Evommune's market cap has decreased from $481.24M to $291.10M, a decrease of -39.51%. That is a compound annual growth rate of -38.38%.
| Date | Market Cap | % Change |
|---|---|---|
| Nov 20, 2026 | 291.10M | -46.06% |
| Dec 31, 2025 | 539.69M | 12.15% |
| Nov 6, 2025 (IPO) | 481.24M | - |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| SL Science Holding | 313.65M |
| X4 Pharmaceuticals | 306.34M |
| ARS Pharmaceuticals | 297.56M |
| Benitec Biopharma | 285.88M |
| Greenwich LifeSciences | 282.56M |
| Precision BioSciences | 282.46M |
| Fulcrum Therapeutics | 281.85M |
| TRex Bio | 281.70M |